News Feature

This week, deals are announced by Eisai, Roivant and Sanofi amongst others.

The week’s announcements began with news from AstraZeneca.

Oncology is currently the leading area for dealmaking, driven by immuno-oncology, which accounted for 32 of the 35 multibillion-dollar oncology licensing deals of the last five years. In this feature, authors at Clarivate Analytics explore the recent trends in oncology deals.

Last week saw another string of high-value deals from the likes of AbbVie, Gilead and Merck & Co., welcome to our weekly round up.

Whilst many of the world’s infectious diseases are managed well due to advances in scientific research, drug-resistant bacterial infections and emerging pathogenic viruses such as Zika still continue to pose major and pressing threats to public health.

Bristol-Myers Squibb (BMS) broke records for the highest licensing fee with its potential $3.8 billion deal with Nektar Therapeutics last Wednesday.

The past week has seen a couple of 1-billion-dollar deals. First, Janssen signed a potential $1 billion deal with Theravance.

As we take our first steps into February, dealmaking activity has quietened down from the boom in recent weeks, but there was still another major M&A announced.

The past week has seen another major M&A deal for the year and it’s not even the end of January.

Two major M&A deals announced today could boost hopes for a spike in dealmaking activity.

Dealmaking has already started in earnest in 2018, with at least 20 deals signed in only the first two weeks. Many of these coincided with the annual JP Morgan conference that has just come to a close, and many of them involve big pharma.

Competition for promising investigational drugs remains fierce, with many assets snapped up before they have even started clinical trials. With the annual JP Morgan conference— typically an event where major deals are announced — now in progress, here we highlight some of the most valuable assets that are currently unpartnered, using data provided by EvaluatePharma.

With a pioneering gene therapy now on the brink of approval, this feature highlights some of the key deals and news in the field in the past five years.

Despite recent clinical trial failures, there is a robust dealmaking and funding environment for companies tackling diseases of the central nervous system, indicating that eventual success is expected.

What are the key steps in preparing nonconfidential material to present to potential partners? In this article, experts at inVentiv Health Consulting discuss how to make the best case for your organization in the current dealmaking climate.

Checkpoint inhibitors continue to achieve clinical and commercial success, which has led to further deals and combination trials as developers look to maximize their reach. In this feature, we update our chart of the development progress and major deals for the leading checkpoint inhibitors.

While breast cancer and ovarian cancer continue to be a major focus of R&D investment and dealmaking, other indications related to women’s health, such as hot flushes and endometriosis, are also attracting interest.

Following on from the success of monoclonal antibodies in oncology, analysts predict big sales from antibody–drug conjugates, while advances in the underlying platforms continue to drive dealmaking.

Data on sales, financing and major deals for vaccines for infectious diseases provide an outlook into the development of the commercial landscape for such products.

Analysis of the deals signed recently by major pharmaceutical companies provides insights into dealmaking strategies.